Institution Directory

Clinical trials at Mount Sinai

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1098

Shown on this page

Current sort

Live official records

Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
Interventions: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, Vincristine Sulfate; Procedure · Biological · Drug + 2 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 365 Days to 25 Years
Enrollment: 5,951 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2032
U.S. locations: 203
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more

Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Interventions: Iadademstat, Gilteritinib Oral Tablet; Drug
Lead sponsor: Oryzon Genomics S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 13
States / cities: Gilbert, Arizona • Tucson, Arizona • Miami, Florida + 9 more

Conditions: Crohn's Disease, Perianal Fistula
Interventions: Mirikizumab, Fistula Tract Curettage and Closure; Drug · Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Louis, Missouri • New York, New York

Conditions: Acute Spinal Cord Injury, Blood Pressure, Hypotension
Interventions: TSCS Mapping, Transcutaneous spinal cord stimulation; Procedure · Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 89 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Atrial Fibrillation, Arrhythmias, Cardiac, Cardiovascular Diseases
Interventions: Physical Activity Intervention Using FitBit Wearable Device; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipatasertib, Magnetic Resonance Imaging, Paclitaxel; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 207
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 167 more

Conditions: Lymphatic Malformation
Interventions: TARA-002; Biological
Lead sponsor: Protara Therapeutics; Industry
Eligibility: 6 Months to 18 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 11
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 8 more

Conditions: Lupus Nephritis
Interventions: Obecabtagene autoleucel; Biological
Lead sponsor: Autolus Limited; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: New York, New York • Syracuse, New York • San Antonio, Texas

Conditions: Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
Interventions: tucatinib, trastuzumab, fulvestrant; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 76
States / cities: Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more

Conditions: Cardiovascular Disease
Interventions: Olpasiran, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 50 Years to 105 Years
Enrollment: 11,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 205
States / cities: Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 170 more

Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Interventions: Zilovertamab vedotin, Nemtabrutinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 20
States / cities: Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 15 more

Conditions: Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Palbociclib; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 264
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 206 more

About this Mount Sinai institution page

What this page lists: ClinicalTrials.gov records that list Mount Sinai in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Mount Sinai

Filter and sort this campus

Live official records

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease

TSCS for Acute SCI

Exercise Activity Intervention With Sensor-Based Engagement in Patients With Atrial Fibrillation

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

About this Mount Sinai institution page